Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Pittsburgh Clinical Genomics Laboratory, |
RCV004785023 | SCV005397443 | uncertain significance | Thrombophilia due to protein C deficiency, autosomal dominant | 2022-09-13 | criteria provided, single submitter | clinical testing | This sequence variant is a single nucleotide substitution (G>A) at coding nucleotide 859 of the PROC gene that results in a valine to isoleucine amino acid change at residue 287 of the PROC protein. The Val287 residue falls in the catalytic domain which plays a critical role in PROC's anticoagulation function (PMID: 32309994). This variant is absent from an online database of clinically annotated variants (ClinVar) but has been reported in individuals with venous thromboembolism in the literature (PMID: 32309994). This variant is present in 12 of 282,718 alleles (0.004%) in the gnomAD control population database. Multiple bioinformatic tools predict that this valine to isoleucine amino acid change would be tolerated, and the Val287 residue is poorly conserved across the vertebrate species examined. The variant amino acid, isoleucine, is present in many mammals, including four primates at the homologous position in these species. Studies examining the functiol consequence of this variant have not been published, to our knowledge. At this time, there is insufficient evidence to determine if this variant is pathogenic or benign. Therefore, we consider this a variant of uncertain significance. ACMG Criteria: BP4, BP5, PM1, PM2, PP1, PP2 |